Expression Pathology Nabs $6.5M Investment from Abraxis to Develop Cancer Drug-Response Dxs | GenomeWeb

Sample-preparation firm Expression Pathology announced two developments this week that could help build its diagnostic pipeline.

The Gaithersburg, Md.-based company said that it has received a $6.5 million investment from a drug maker, which it said it plans to use to continue developing pharmacogenomic clinical assays on its flagship technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.